Imunologia da hanseníase

Mendonça, Vanessa Amaral; Costa, Rosane Dias; Melo, Gustavo Eustáquio Brito Alvim de; Antunes, Carlos Maurício de Figueiredo; Teixeira, Antônio Lúcio

doi:10.1590/s0365-05962008000400010

Cited by 54 publications

(36 citation statements)

References 70 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, clinical manifestations are characterized by neural and/or skin impairment, which may be unobtrusive and imperceptible at disease onset 2 . A vigilant attitude should be maintained towards physical changes from leprosy infection.…”

Section: Introductionmentioning

confidence: 99%

Assessment of the sensory and physical limitations imposed by leprosy in a Brazilian Amazon Population

Aben-Athar

Lima

Ishak

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Leprosy often results in sensory and physical limitations. This study aimed to evaluate these limitations using a quantitative approach in leprosy patients in Belém (Pará, Brazil). Methods: This epidemiological, cross-sectional study measured the sensory impairment of smell and taste through the use of a questionnaire and evaluated activity limitations of daily life imposed by leprosy through the Screening of Activity Limitation and Safety Awareness (SALSA) Scale. Data were collected from 84 patients and associations between the degree of disability and clinical and epidemiological characteristics were assessed. Results: The majority of patients were men (64.3%), married (52.4%), age 31-40 years old (26.2%), had primary education (50%), and were independent laborers (36.9%). The multibacillary operational classification (81%), borderline clinical form (57.1%), and 0 degrees of physical disability (41.7%) were predominant. SALSA scores ranged from 17 to 59 points, and being without limitations was predominant (53.6%). The risk awareness score ranged from 0 to 8, with a score of 0 (no awareness of risk) being the most common (56%). Evaluation of smell and taste sensory sensitivities revealed that 70.2% did not experience these sensory changes. Patients with leprosy reactions were 7 times more likely to develop activity limitations, and those who had physical disabilities were approximately four times more likely to develop a clinical picture of activity limitations. Conclusions: Most patients showed no sensory changes, but patients with leprosy reactions were significantly more likely to develop activity limitations. Finally, further studies should be performed, assessing a higher number of patients to confirm the present results.

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of the sensory and physical limitations imposed by leprosy in a Brazilian Amazon Population

Aben-Athar

Lima

Ishak

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

show abstract

“…This fact indicates that there is an association of genetic and environmental factors on susceptibility and cause of resistance 1,2 . The correct diagnosis of leprosy requires evolutionary clinical data of the disease, histopathological analysis and sputum smear microscopy, enabling determination of the form presented by the patient, such as: TT (tuberculoid), BT (borderline tuberculoid), BB (borderline borderline), BL (borderline lepromatous) and LL (lepromatous leprosy) 3,4,5 . This classification is necessary for the appropriate, specific therapeutic option to be delivered 6,7 .…”

Section: Introductionmentioning

confidence: 99%

“…These forms range from tuberculoid, with a predominantly cellular immune response, to lepromatous leprosy dominated by a humoral response 4,11 . These responses are associated with specific mechanisms for the recognition of antigens, mediated by receptors present on the membranes of T and B lymphocytes 12,13 .…”

Section: Introductionmentioning

confidence: 99%

Analysis of clinical data and T helper 1/T helper 2 responses in patients with different clinical forms of leprosy

Rodrigues

Ribeiro

Berber³

et al. 2017

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Currently, there are no laboratory tests or sensitive and specific molecular markers for the early diagnosis of leprosy. The aim of this study was to analyze the clinical characteristics of patients with leprosy and investigate their immunological profile, comparing this with the type of lesion and the presence or absence of a Bacillus Calmette-Guérin (BCG) vaccination scar. Methods: Statistical analyzes were performed by employing comparative tests (Pearson´s chi-square) to evaluate the variables in different clinical forms, considering significance at the 5% level. Results: The study identified a predominance of lepromatous leprosy (26.9%) in patients aged between 34-53 years. Caucasians predominantly had borderline tuberculoid (BT) clinical forms (42%); a predominance of males with borderline lepromatous (19%) and lepromatous leprosy (26.9%) forms was observed; and the presence of BCG vaccination scars (27.5%) and lower limb nerves were more affected (38%) predominantly in the BT clinical form. Significant differences were identified, which included hypochromic lesions predominantly in the BT clinical form (24%); diffuse-type lesions predominantly in the tuberculoid (TT) clinical form (28%); ill-defined lesion border dominance in lepromatous leprosy (LL) clinical forms (30%); an irregular lesion limit predominantly in LL clinical forms (32%); and a predominant Th1 immune response in the BT clinical form (41.7%). Conclusions: The evaluation of the immunological profile in leprosy patients may contribute to the more detailed diagnosis and possibly better characterization of the prognosis for these individuals.

show abstract

“…It can be better understood when regarded as an association of two diseases: first, a chronic infection that induces a cell-mediated immune response; second, a peripheral neuropathy which is triggered by infection and followed by a series of immunological events, whose evolution, sequels and disabilities often last many years, even after infection has ceased [4][5][6][7] . Leprosy still remains the commonest cause of peripheral neuropathy in developing countries 8 .…”

mentioning

confidence: 99%

Study of the profile of the neurotrophin BDNF in new leprosy cases before, during and after multidrug therapy

Costa

Mendonça

Penido³

et al. 2011

Arq. Neuro-Psiquiatr.

Self Cite

View full text Add to dashboard Cite

Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the survival of neurons and growth and differentiation of dendrites and axons. The purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients at different stages of multidrug therapy (MDT) in comparison with non-infected individuals. Plasma levels of BDNF were measured by ELISA in 30 healthy controls and 37 leprosy patients at diagnosis, during and after MDT. Plasma levels of BDNF tended to be higher in control subjects in comparison with leprosy patients, but this difference does not reach statistical significance. Interestingly, BDNF levels changed following MDT, achieving statistical difference only at the 2 nd dose of MDT. These results indicate that BDNF may not be a surrogate marker of leprosy infection and/or related neuropathy. Further research is needed to investigate the meaning of BDNF level changes following leprosy treatment. Key words: leprosy, BDNF, peripheral neuropathy, biomarker, follow-up.Estudo do perfil da neurotrofina BDNF em casos novos de hanseníase antes, durante e após poliquimioterapia RESUMO O fator neurotrófico derivado do cérebro (BDNF) é uma neurotrofina envolvida na sobrevivência neuronal e no crescimento e diferenciação dos dendritos e axônios. O objetivo do presente estudo foi avaliar os níveis plasmáticos do BDNF de pacientes com hanseníase em diferentes fases da poliquimioterapia (PQT), em comparação com indivíduos não-infectados. Os níveis plasmáticos do BDNF foram mensurados pelo teste ELISA em 30 controles sadios e 37 pacientes com hanseníase no momento do diagnóstico, durante e após PQT. Os níveis plasmáticos do BDNF mostraram-se maiores nos indivíduos controles em comparação com os pacientes com hanseníase, mas não houve diferença estatisticamente significante. Curiosamente, os níveis de BDNF modificaram-se com o tratamento, mostrando diferença estatística apenas na segunda dose de PQT. Esses resultados indicam que o BDNF pode não ser um marcador de infecção na hanseníase e/ ou neuropatias relacionadas. Novas pesquisas são necessárias para investigar o significado das alterações nos níveis de BDNF ao longo do tratamento da hanseníase. Palavras-chave: hanseníase, BDNF, neuropatia periférica, biomarcador, seguimento.

show abstract

Imunologia da hanseníase

Cited by 54 publications

References 70 publications

Assessment of the sensory and physical limitations imposed by leprosy in a Brazilian Amazon Population

Assessment of the sensory and physical limitations imposed by leprosy in a Brazilian Amazon Population

Analysis of clinical data and T helper 1/T helper 2 responses in patients with different clinical forms of leprosy

Study of the profile of the neurotrophin BDNF in new leprosy cases before, during and after multidrug therapy

Contact Info

Product

Resources

About